{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T23:38:15Z","timestamp":1792712295815,"version":"4.5.0"},"reference-count":13,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100012482","name":"University of Michigan Comprehensive Cancer Center","doi-asserted-by":"publisher","award":["2-P30-CA-046592-24"],"award-info":[{"award-number":["2-P30-CA-046592-24"]}],"id":[{"id":"10.13039\/100012482","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R37CA283857"],"award-info":[{"award-number":["R37CA283857"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","eu-focus.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Focus"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.euf.2026.10.007","type":"journal-article","created":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T21:02:03Z","timestamp":1792616523000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Risk-stratified Prostate Cancer Screening in 2026: Blood- and Urine-based Biomarkers"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8644-2445","authenticated-orcid":false,"given":"Judith","family":"Stangl-Kremser","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simpa S.","family":"Salami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euf.2026.10.007_b0005","doi-asserted-by":"crossref","DOI":"10.1177\/17562872221103988","article-title":"Biomarkers for prostate cancer detection and risk stratification","volume":"14","author":"Farha","year":"2022","journal-title":"Ther Adv Urol"},{"key":"10.1016\/j.euf.2026.10.007_b0010","article-title":"Prostate\u2010specific antigen (PSA) test for prostate cancer screening","volume":"5","author":"Franco","year":"2026","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.euf.2026.10.007_b0015","unstructured":"Early detection of prostate cancer: AUA\/SUO guideline; 2023. American Urological Association [Internet], https:\/\/www.auanet.org\/guidelines-and-quality\/guidelines\/early-detection-of-prostate-cancer-guidelines; (accessed 2026 Jan 26)."},{"key":"10.1016\/j.euf.2026.10.007_b0020","unstructured":"EAU guidelines on prostate cancer-diagnostic evaluation. Edn. presented at the EAU Annual Congress London 2026. EAU Guidelines Office, Arnhem, The Netherlands."},{"key":"10.1016\/j.euf.2026.10.007_b0025","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1056\/NEJMoa2407934","article-title":"Assessment of a polygenic risk score in screening for prostate cancer","volume":"392","author":"McHugh","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euf.2026.10.007_b0030","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1038\/s41391-022-00497-7","article-title":"Prostate cancer risk stratification improvement across multiple ancestries with new polygenic hazard score","volume":"25","author":"Huynh-Le","year":"2022","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.euf.2026.10.007_b0035","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.eururo.2014.08.010","article-title":"Comparison between the four-kallikrein panel and prostate health index for predicting prostate cancer","volume":"68","author":"Nordstr\u00f6m","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2026.10.007_b0040","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1016\/S1470-2045(15)00361-7","article-title":"Prostate cancer screening in men aged 50\u201369 years (STHLM3): a prospective population-based diagnostic study","volume":"16","author":"Gr\u00f6nberg","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euf.2026.10.007_b0045","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1056\/NEJMoa2406050","article-title":"Results after four years of screening for prostate cancer with PSA and MRI","volume":"391","author":"Hugosson","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euf.2026.10.007_b0050","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.eururo.2024.04.030","article-title":"Risk-adjusted screening for prostate cancer-defining the low-risk group by data from the PROBASE trial","volume":"86","author":"Krilaviciute","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2026.10.007_b0055","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/s41391-017-0024-7","article-title":"Prostate-specific antigen (PSA) density in the diagnostic algorithm of prostate cancer","volume":"21","author":"Nordstr\u00f6m","year":"2018","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.euf.2026.10.007_b0060","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/bju.15277","article-title":"Risk-adapted biopsy decision based on prostate magnetic resonance imaging and prostate-specific antigen density for enhanced biopsy avoidance in first prostate cancer diagnostic evaluation","volume":"127","author":"Schoots","year":"2021","journal-title":"BJU Int"},{"key":"10.1016\/j.euf.2026.10.007_b0065","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1001\/jama.2024.3841","article-title":"Prostate cancer screening with PSA, kallikrein panel, and MRI: the ProScreen randomized trial","volume":"331","author":"Auvinen","year":"2024","journal-title":"JAMA"}],"container-title":["European Urology Focus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456926002312?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456926002312?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T22:48:09Z","timestamp":1792709289000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405456926002312"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":13,"alternative-id":["S2405456926002312"],"URL":"https:\/\/doi.org\/10.1016\/j.euf.2026.10.007","relation":{},"ISSN":["2405-4569"],"issn-type":[{"value":"2405-4569","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk-stratified Prostate Cancer Screening in 2026: Blood- and Urine-based Biomarkers","name":"articletitle","label":"Article Title"},{"value":"European Urology Focus","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euf.2026.10.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}